The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

Boston Scientific has launched a docuseries campaign to remove the stigma of male incontinence. Across the videos, the campaign tells the stories of how incontinence upended the lives of three men ...

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Recommendations on management of patients with implantable cardiac devices undergoing radiotherapy are based on limited studies mostly involving pacemakers ... 2002 Boston Scientific ICD 2 ...

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the consensus estimate of $4.04 billion. Sales increased 19.4% on a reported basis ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...

St. Jude CRT-ICD 1 Atlas +HF (V-343) 2004 St. Jude ICD 1 Epic +VR (V-196) 2001 St. Jude CRT-ICD 1 Epic HF (V-337) 2004 St. Jude ICD 2 Epic +DR (V-239) 2002 Boston Scientific ICD 2 Vitality DS ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...